R&D Strategies Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity

Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design. However, as the low-hanging fruit has been picked, and recent technological advances have failed to yield high numbers of new therapies, the search is on to identify R&D strategies to improve R&D productivity

Scope of this report

* Overview of the pressures facing drug developers, including an analysis of whether the industry is facing an R&D productivity crisis

* In-depth analysis of R&D deal activity, together with a pipeline snapshot, to identify trends that are shaping the R&D environment

* Identification of strategy optimization recommendations designed to drive up R&D productivity

* Evaluation of case-studies of Big Pharma R&D strategies to determine how these companies are addressing the productivity problem

Research and analysis highlights

Over the last decade, significant investment in novel technologies has failed to yield a substantial increase in innovative drugs

To drive up future productivity, drug developers are making either incremental changes to fine-tune the R&D process or they are implementing paradigm changes to radically alter the way that R&D is carried out

R&D productivity depends on accelerating and boosting the output of drug discovery and development, and there are a range of strategies to do this, including optimizing the R&D model and improving the R&D process

Key reasons to read this report

* Gain a clear understanding of the factors driving drug developers to change R&D strategies

* Gain insight into the trends in R&D clinical pipeline deal activity and pipeline focus

* Understand how a wide of strategies can optimize R&D productivity and identify how these can best be implemented

Published: 9 August 2007

PDF Format
Table of Contents
Price: $15,200.00 / GBP7,600.00